- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00872092
Validation of Breath Tests in Diagnosing Small Bowel Bacterial Overgrowth (BTO)
March 30, 2009 updated by: University Hospital, Bonn
Normally the gastrointestinal tract is only sparsely colonized with bacteria.
The normal flora of the duodenal or jejunal aspirate contains no more than 10^5 bacteria per milliliter.
Small bowel bacterial overgrowth (SBBO) is defined as a pathologically increased number of bacteria or the presence of colonic flora in the proximal intestine.
The reasons for this condition are manifold, ranging from diabetic neuropathy to surgical bypass.
SBBO is frequent in elderly people.
Therapy is targeted at correcting the underlying small bowel abnormalities that predispose to the condition and at providing appropriate antibiotic therapy.
The symptoms and signs of SBBO can be reversed with this approach.
However, in many patients the conditions predisposing to SBBO persist life-long, once present.
This suggests that noninvasive, sensitive diagnostic tools with high specificity are required.
Bacterial culture of upper intestinal content is considered the diagnostic gold standard.
However, since endoscopic harvesting of duodenal or jejunal fluid is difficult and invasive, indirect tests such as breath tests have been advocated as diagnostic tools.
Hydrogen breath tests are commonly employed since the substrates can be easily obtained and the measurement is simple.
Hydrogen is formed when carbohydrates are fermented in the intestine.
Breath hydrogen analysis allows a separation of metabolic activity of the intestinal flora from that of the host, since no known hydrogen production occurs in mammalian tissue.
The hydrogen breath test most often used in routine clinical practice uses glucose.
However, the utility of this test is mostly limited by its low sensitivity, because there are "nonproducers" in up to 25% of the subjects tested.
The investigators have developed a stable isotope breath test using 13C-labeled lactose-ureide.
Glycosyl-ureides are condensation products of reducing sugars and urea in aqueous acid.
Lactose-[13C]ureide has been used to investigate oro-caecal transit time because it resists digestion by small intestinal enzymes and is hydrolyzed by bacterial enzymes in the large intestine.
A number of studies have described the use of this substrate in adults and children.
The aim of the present study was to investigate the lactose-[13C]ureide breath test in subjects with suspected SBBO and to compare its results with the results of the glucose hydrogen breath test.
Microbiological analyses of upper intestinal bacterial cultures were used as gold standard to identify SBBO.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
22
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bonn, Germany, 53105
- University of Bonn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with suspected small bowel bacterial overgrowth
Description
Inclusion Criteria:
- Suspected small bowel bacterial overgrowth
Exclusion Criteria:
- Age < 18 years
- Antibiotic therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Breath test
Subjects with suspected SBBO
|
2 g 13C-labeled lactose ureide orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
13CO2 enrichment in breath CO2
Time Frame: 3 hours
|
3 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Hydrogen output in breath
Time Frame: 3 hours
|
3 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 1997
Primary Completion (Actual)
September 1, 1998
Study Completion (Actual)
September 1, 1998
Study Registration Dates
First Submitted
March 30, 2009
First Submitted That Met QC Criteria
March 30, 2009
First Posted (Estimate)
March 31, 2009
Study Record Updates
Last Update Posted (Estimate)
March 31, 2009
Last Update Submitted That Met QC Criteria
March 30, 2009
Last Verified
March 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTO-0001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.